## 504237782 02/21/2017

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4284459

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
JULIEN BEIGNET	08/02/2016
STEPHEN JACKSON	08/11/2016
DWIGHT MACDONALD	08/11/2016
HELMUT THOMAS	08/11/2016
AMAL WAHHAB	08/11/2016

#### **RECEIVING PARTY DATA**

Name:	OCERA THERAPEUTICS, INC.
Street Address:	525 UNIVERSITY AVENUE, SUITE 610
City:	PALO ALTO
State/Country:	CALIFORNIA
Postal Code:	94301

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	15336128

### **CORRESPONDENCE DATA**

**Fax Number:** (650)952-9881

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 650-467-8688
Email: tarah@gene.com
Correspondent Name: MARK D. KAFKA
Address Line 1: GENENTECH, INC.

Address Line 2: 1 DNA WAY

Address Line 4: SOUTH SAN FRANCISCO, CALIFORNIA 94080

NAME OF SUBMITTER: MARK D	
	. KAFKA
SIGNATURE: /Mark D.	Kafka/
<b>DATE SIGNED:</b> 02/21/20	17

**Total Attachments: 10** 

source=P32499-US Assignment I Ocera inventors#page1.tif	
source=P32499-US Assignment I Ocera inventors#page2.tif	
source=P32499-US Assignment I Ocera inventors#page3.tif	
source=P32499-US Assignment I Ocera inventors#page4.tif	
source=P32499-US Assignment I Ocera inventors#page5.tif	
source=P32499-US Assignment I Ocera inventors#page6.tif	
source=P32499-US Assignment I Ocera inventors#page7.tif	
source=P32499-US Assignment I Ocera inventors#page8.tif	
source=P32499-US Assignment I Ocera inventors#page9.tif	
source=P32499-US Assignment   Ocera inventors#page10.tif	

THIS CONFIRMATORY ASSIGNMENT INSTRUMENT (this Instrument) is dated as of August 15, 2016 and is made by and among:

- (1) JULIEN BEIGNET, an individual residing at 131 rue de la Guesierie, 44150 Saint-Herblon, France (Julien);
- (2) STEPHEN JACKSON, an individual residing at 1292 rue de Saturne, Lévis (Québec) G6W 8H8, Canada (Stephen);
- (3) DWIGHT MACDONALD, an individual residing at 113 Windward Crescent, Pointe-Claire (Québec) H9R 2H7, Canada (Dwight);
- (4) HELMUT THOMAS, an individual residing at 4366 rue Michel-Ange, Sherbrooke (Québec) J1N 1R6, Canada (Helmut);
- (5) AMAL WAHHAB, an individual residing at 954 Dickens Crescent, Laval (Québec) H7W 4E1, Canada (Amal, and collectively with Julien, Stephen, Dwight and Helmut, the Inventors); and
- (6) OCERA THERAPEUTICS, INC., a corporation existing under the laws of the State of Delaware (Ocera, and together with the Inventors, the Parties).

#### RECITALS:

- (A) WHEREAS the Inventors were formerly employees of Tranzyme Pharma Inc. (formerly Neokimia Inc.) (Tranzyme Pharma) and, in their capacity as such, all inventions, creations, discoveries, processes or information generated, developed, created or conceived by them during the course of their employment were considered work created within the framework of their employment and, consequently, any intellectual property and intellectual property rights obtained, created or derived therefrom became the exclusive property of Tranzyme Pharma;
- (B) WHEREAS during the course of their employment, the Inventors participated in the inventions, discoveries or other activities which ultimately resulted in the intellectual property that permitted the filing of an application for a patent with the European Patent Office bearing number EP 15191743.2 (the European Patent);
- (C) WHEREAS pursuant to a sale, transfer and assignment agreement (the Assignment Agreement) entered into between Tranzyme Pharma, as seller, transferor and assignor, and Ocera, as purchaser, transferee and assignee, dated December 13, 2013 (the Assignment Date), Tranzyme Pharma sold, transferred and assigned to Ocera the universality of its assets, property, equipment, inventory and licensing and other contractual rights, including without limitation, all intellectual property and intellectual property rights then held or owned by Tranzyme Pharma;
- (D) WHEREAS, as of the Assignment Date, all rights associated with the European Patent were owned and held by Tranzyme Pharma and, consequently, were intended to be and were in fact and in law assigned to Ocera under the Assignment Agreement;
- (E) WHEREAS pursuant to a technology transfer and license agreement (the License Agreement) entered into among Ocera, as transferor and licensor, and Genentech, Inc. and F. Hoffmann-La Roche Ltd. (collectively, the Licensee), as licensees and transferees, dated as of the Assignment Date, Ocera, inter alia, irrevocably, perpetually and exclusively licensed to the Licensee certain of its intellectual property and intellectual property rights, including without limitation, the intellectual property and intellectual property rights underlying and comprising the European Patent;
- (F) WHEREAS Tranzyme Pharma was dissolved and ceased to exist on December 14, 2015; and

CAN\_DMS: \103019823\6

(G) WHEREAS the Parties wish to enter into this Instrument to confirm their understanding in respect of Ocera's right, title and interest in and to the European Patent.

NOW THEREFORE, in consideration of the foregoing premises and other good and valuable consideration, the receipt and sufficiency of which are acknowledged by the Parties, the Parties agree as follows.

### Article 1 Interpretation

#### 1.1 Gender and Number

Any reference in this Instrument to gender includes all genders and words importing the singular include the plural and vice versa.

#### 1.2 Certain Phrases

In this Instrument (a) the words "including" and "includes" mean "including (or includes) without limitation"; (b) the terms "this Instrument", "hereof", "herein", "hereby", "hereunder" and similar expressions refer to this Instrument and not to any particular Article or Section.

### 1.3 Headings, Etc.

The division of this Instrument into Articles and Sections and the insertion of headings are for convenient reference only and are not to affect or be used in the construction or interpretation of this Instrument.

### 1.4 Governing Law

- (a) This Instrument is governed by and is to be interpreted, construed and enforced in accordance with the laws of the Province of Quebec, Canada, without regard to conflict of law principles.
- (b) Each of the Parties irrevocably attorns and submits to non-exclusive jurisdiction of the courts of the Province of Quebec in any action or proceeding arising out of or relating to this Instrument. Each of the Parties waives objection to the venue of any action or proceeding in such court or any argument that such court provides an inconvenient forum.

### Article 2 Confirmation of Assignment

### 2.1 Confirmation by the Inventors

The Inventors hereby acknowledge, agree and confirm that:

- (a) in their capacity as former employees of Tranzyme Pharma, the Inventors, during and as part of the course of their employment for Tranzyme Pharma, validly assigned, transferred and conveyed to Tranzyme Pharma all of their right, title and interest in, to or arising from or relating to the intellectual property and the intellectual property rights underlying and comprising the European Patent;
- (b) they have no, and will not now or in the future claim any, commercial, monetary or economic rights, title or interest in, to or arising from or relating to the intellectual property and the intellectual property rights underlying and comprising the European Patent;

2

- (c) prior to the Assignment Date, Tranzyme Pharma was the lawful holder of all right, title and interest in and to the European Patent;
- (d) Tranzyme Pharma assigned, conveyed and transferred all right, title and interest in and to the intellectual property and the intellectual property rights underlying and comprising the European Patent to Ocera as part of the Assignment Agreement, and that Ocera became the lawful assignee of the intellectual property and the intellectual property rights underlying and comprising the European Patent pursuant to the Assignment Agreement; and
- (e) Ocera irrevocably, perpetually and exclusively licensed all right, title and interest in and to the intellectual property and the intellectual property rights underlying and comprising the European Patent to the Licensee pursuant to the License Agreement.

### 2.2 Confirmation by Ocera

Ocera hereby acknowledges, agrees and confirms that:

- (a) Tranzyme Pharma assigned, conveyed and transferred to Ocera, and Ocera obtained, all right, title and interest in and to the intellectual property and the intellectual property rights underlying and comprising the European Patent as part of the Assignment Agreement;
- (b) it became the lawful holder of all right, title and interest in and to the intellectual property and the intellectual property rights underlying and comprising the European Patent pursuant to the Assignment Agreement; and
- (c) it irrevocably, perpetually and exclusively licensed all right, title and interest in and to the intellectual property and the intellectual property rights underlying and comprising the European Patent to the Licensee pursuant to the License Agreement.

### Article 3 Miscellaneous

#### 3.1 Amendments

This Instrument may only be amended, supplemented or otherwise modified by written agreement of all of the Parties.

#### 3.2 Further Assurances

Each of the Parties shall, from time to time, do all such acts and things and execute and deliver, from time to time, all such further documents and assurances as may be reasonably necessary to carry out and give effect to the terms of this Instrument.

#### 3.3 Severability

If a provision of this Instrument is determined by a court of competent jurisdiction to be illegal, invalid or unenforceable, that provision is to be severed from this Instrument and the remaining provisions will continue in full force and effect, without amendment.

#### 3.4 Counterparts

This Instrument may be executed in any number of separate counterparts (including by facsimile or other electronic means) and all such signed counterparts will together constitute one and the same agreement. To evidence its execution of an original counterpart of this Instrument, a Party may send a copy of its original signature on the execution page hereof to the other Parties

by facsimile or other means of recorded electronic transmission and such transmission (including in PDF form) shall constitute delivery of an executed copy of this Instrument to the receiving Party.

# 3.5 English Language

The Parties have specifically requested this Instrument to be drawn up in the English language. Les parties aux présentes ont exigé que la présente convention soit rédigée en langue anglaise.

[Signature pages follow]

4

IN WITNESS WHEREOF the Parties have executed and delivered this Instrument as of the date first written above.

Julien Beignet

Je sonssigné Julien BEIGNET déclare que la signatur d'adossus est conforme et déclare avoir mon entière capacité.

> FAIT à : VARADES, 44 370, FRANCE Le deux Août Deux Mülle Seige (2/08/2015)

> > ) Usin Tillian

JE SOUSSIGNE Mª ÁRRAGEZ TERRONE
Notaire à VARADES
certifie exacte la signature de
M. TARRA ARRONEZ
apposée ci-contre
A. VARATET

Notaire/

Confirmatory Assignment Instrument

Stephen Jackson

# CERTIFICATION

I, the undersigned, Nancy Latonics	, a Commissioner for Oaths for all the districts of
the Province of Quebec, residing and domiciled	at <u>0606 bool Lours (bur, lStr</u> ), at the City of
in the said Province, do certify	and attest that I have verified the identity and
	gned the aforesaid Confirmatory Assignment
Instrument on the <u>Itak</u> day of <u>August</u>	, 2016.
	AND I HAVE SIGNED:
	Wentury Turking in
	*
Solemnly declared before me	
in <u>C. Els.c.</u> , on <u>August //</u> 2019	
William Control of the Control of th	
	- 400 × 1
Am Cara	
	8924 <b>V</b>
Commissioner of Oaths for Quebec	
Nancy Words	
*	

Dwight Macdonald

I, the undersigned, What Gen-Alma a Commissioner for Oaths for all the districts of the Province of Quebec, residing and domiciled at 536 Provost at the City of Lachure in the said Province, do certify and attest that I have verified the identity and capacity of Twist MacDenald, who signed the aforesaid Confirmatory Assignment Instrument on the Item day of 1961.

\*\*\*\*

AND I HAVE SIGNED:


Solemply declared before me

in St-Lavent, on 11th 4 12ust, 2016

Commissioner of Oaths for Quebec

Immaula Ben-Ame





## CERTIFICATION

I, the undersigned, MMacus Och Aryuche Province of Quebec, residing and domiciled Lachure, in the said Province, do certify capacity of Ichur Thomas, who signstrument on the May of Propus	and attest that I have verified the identity and gned the aforesaid Confirmatory Assignment
	AND I HAVE SIGNED:
	Buli
Solemnly declared before me	
in SF-Taurut, on 11th of August, 2016	
Dai	- America - S
Commissioner of Oaths for Quebec	208,853
Immacula Poon-Anne	

Ang Walla De Amai Wahhab

## CERTIFICATION

\*\*\*\*\*

	at the City of attest that I have verified the identity and the aforesaid Confirmatory Assignment
ANI	O I HAVE SIGNED:
Solemnly declared before me,	
in St-lavered, on 1th of Avgust, 2016	
Beci	
Commissioner of Oaths for Quebec	

Per: Name: (Date) CITY OF STATE OF COUNTRY OF CERTIFICATION day of A Low LOK , 2016, before me personally came the above named (signing on behalf of Ocera Therapeutics, Inc.) who is personally known by me or provided to me on the basis of satisfactory evidence to be the same individual who executed the foregoing Confirmatory Assignment Instrument, and who acknowledged to math that he/she executed the same of his/her own free will for the use and purposes thereig set forth. **NOTARY PUBLIC** fflison ? Print Name of Notary State of Californical Large My Commission Expires:

Confirmatory Assignment Instrument

Personally Known \_\_\_\_\_ or Produced I.D. \_\_\_\_

Type of Identification Produced DL

OCERA THERAPEUTICS, INC.